194 related articles for article (PubMed ID: 36949059)
1. CACNA1D overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation.
McKerr N; Mohd-Sarip A; Dorrian H; Breen C; A James J; McQuaid S; Mills IG; McCloskey KD
Sci Rep; 2023 Mar; 13(1):4683. PubMed ID: 36949059
[TBL] [Abstract][Full Text] [Related]
2. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
3. Data pertaining to aberrant intracellular calcium handling during androgen deprivation therapy in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan P
Data Brief; 2022 Jun; 42():108143. PubMed ID: 35496494
[TBL] [Abstract][Full Text] [Related]
4. Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers.
Chen R; Zeng X; Zhang R; Huang J; Kuang X; Yang J; Liu J; Tawfik O; Thrasher JB; Li B
Urol Oncol; 2014 Jul; 32(5):524-36. PubMed ID: 24054868
[TBL] [Abstract][Full Text] [Related]
5. [Impact of calcium channel antagonists for estrogen action on the endometrial carcinoma HEC-1A cells].
Bao XX; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):212-7. PubMed ID: 22781074
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer.
Shima T; Mizokami A; Miyagi T; Kawai K; Izumi K; Kumaki M; Ofude M; Zhang J; Keller ET; Namiki M
Prostate; 2012 Dec; 72(16):1789-801. PubMed ID: 22549914
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
Kim J; Park S; Kim S; Ryu S; Hwang H; Cho S; Han Y; Kim J; Park Y; Lee EK; Lee M
Prostate; 2024 Jun; 84(9):814-822. PubMed ID: 38558458
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.
Khurana N; Talwar S; Chandra PK; Sharma P; Abdel-Mageed AB; Mondal D; Sikka SC
Int J Oncol; 2016 Oct; 49(4):1609-19. PubMed ID: 27499349
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
Filon MJ; Gillette AA; Yang B; Khemees TA; Skala MC; Jarrard DF
Prostate; 2022 Dec; 82(16):1547-1557. PubMed ID: 35980831
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
12. Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Yoshikawa Y; Stopsack KH; Wang XV; Chen YH; Mazzu YZ; Burton F; Chakraborty G; Rajanala SH; Hirani R; Nandakumar S; Lee GM; Frank D; Davicioni E; Liu G; Carducci MA; Azuma H; Kantoff PW; Sweeney CJ
Mol Oncol; 2022 Dec; 16(22):3994-4010. PubMed ID: 36087093
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
14. Benzyldihydroxyoctenone, a novel nonsteroidal antiandrogen, shows differential apoptotic induction in prostate cancer cells in response to their androgen responsiveness.
Suh H; Oh HL; Lee CH
J Microbiol Biotechnol; 2011 May; 21(5):540-4. PubMed ID: 21617354
[TBL] [Abstract][Full Text] [Related]
15. [Role of Ca
Sekiguchi F; Kawabata A
Nihon Yakurigaku Zasshi; 2019; 154(3):97-102. PubMed ID: 31527367
[TBL] [Abstract][Full Text] [Related]
16. Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer.
Sasaki T; Ishii K; Iwamoto Y; Kato M; Miki M; Kanda H; Arima K; Shiraishi T; Sugimura Y
Lab Invest; 2016 Mar; 96(3):338-49. PubMed ID: 26641067
[TBL] [Abstract][Full Text] [Related]
17. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
18. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
[TBL] [Abstract][Full Text] [Related]
19. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
20. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]